About NicOx (OTCMKTS:NICXF)
Nicox S.A., an ophthalmic company, researches, develops, and markets therapies that target various ophthalmic conditions in France and internationally. The company's product pipeline includes VyzultaTM, an intra-ocular pressure-lowering treatment; and NCX 470, a nitric oxide (NO)-donating candidate to treat glaucoma, as well as stand-alone NO donors for specific applications in ophthalmic diseases. It also provides ZERVIATE, an eye drop formulation of cetirizine for allergic conjunctivitis; AC-120, an eye drop that targets morning eyelid swelling; NCX 4240, a Carragelose eye drop for the treatment of for viral conjunctivitis; and NCX 4251, a patented suspension of fluticasone propionate nanocrystals to treat blepharitis. The company has collaborations with Bausch + Lomb, Astra Zeneca, Merck, Pfizer, and pSivida Corp. Nicox S.A. was founded in 1996 and is headquartered in Valbonne, France.
Industry, Sector and Symbol
Trailing P/E RatioN/A
Forward P/E RatioN/A
Sales & Book Value
Price / Sales16,730.96
Price / CashN/A
Book Value$4.18 per share
Price / Book2.71
Return on EquityN/A
Return on AssetsN/A
NicOx (OTCMKTS:NICXF) Frequently Asked Questions
What is NicOx's stock symbol?
NicOx trades on the OTCMKTS under the ticker symbol "NICXF."
When will NicOx make its next earnings announcement?
Who are some of NicOx's key competitors?
Some companies that are related to NicOx include Arrowhead Pharmaceuticals (ARWR), Endocyte (ECYT), Lannett (LCI), Odonate Therapeutics (ODT), ZIOPHARM Oncology (ZIOP), Mesoblast (MESO), Fate Therapeutics (FATE), Rhythm Pharmaceuticals (RYTM), Progenics Pharmaceuticals (PGNX), GlycoMimetics (GLYC), Reata Pharmaceuticals (RETA), Rigel Pharmaceuticals (RIGL), Agenus (AGEN), NuCana (NCNA), BeyondSpring (BYSI), Akebia Therapeutics (AKBA), Clementia Pharmaceuticals (CMTA) and Aclaris Therapeutics (ACRS).
Who are NicOx's key executives?
NicOx's management team includes the folowing people:
- Mr. Michele Garufi, Co-Founder, Chairman & CEO (Age 64)
- Dr. Elizabeth Marie Robinson, Co-Founder and Pres of the Nicox Research Institute Srl (Age 62)
- Mrs. Sandrine Gestin, VP of Fin. (Age 51)
- Dr. Michael V. W. Bergamini Ph.D., Chief Scientific Officer & Exec. VP (Age 71)
- Mrs. Emmanuelle Pierry, Sr. Director of Legal Affairs
Has NicOx been receiving favorable news coverage?
News stories about NICXF stock have been trending positive this week, Accern reports. Accern scores the sentiment of news coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. NicOx earned a news impact score of 0.35 on Accern's scale. They also gave headlines about the company an impact score of 46.35 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company's share price in the near term.
How do I buy shares of NicOx?
Shares of NICXF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is NicOx's stock price today?
One share of NICXF stock can currently be purchased for approximately $11.32.
How big of a company is NicOx?
NicOx has a market capitalization of $326.88 million and generates $20,000.00 in revenue each year. NicOx employs 28 workers across the globe.
How can I contact NicOx?
NicOx's mailing address is Drakkar 2 - Batiment D 2405 route des Dolines - CS 10313 Sophia Antipolis Cedex, Valbonne I0, 06560. The company can be reached via phone at 33-4-97-24-53-00.
MarketBeat Community Rating for NicOx (NICXF)MarketBeat's community ratings are surveys of what our community members think about NicOx and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
NicOx (OTCMKTS:NICXF) Analyst Ratings History
No equities research coverage for this company has been tracked by MarketBeat
Earnings History for NicOx (OTCMKTS:NICXF)
No earnings announcements for this company have been tracked by MarketBeat.com
NicOx (OTCMKTS:NICXF) Earnings Estimates
No earnings estimates for this company have been tracked by MarketBeat.com
Dividend History for NicOx (OTCMKTS:NICXF)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading History for NicOx (OTCMKTS NICXF)
No insider trades for this company have been tracked by MarketBeat.com
NicOx (OTCMKTS NICXF) News Headlines
NicOx (OTCMKTS:NICXF) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Financials are not available for this stock.
NicOx (OTCMKTS NICXF) Stock Chart for Tuesday, March, 20, 2018